- Home
- FHTX vs TEI Comparison
FHTX vs TEI Comparison
Compare FHTX & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- TEI
- Stock Information
- Founded
- FHTX 2015
- TEI 1993
- Country
- FHTX United States
- TEI United States
- Employees
- FHTX N/A
- TEI N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- TEI Finance Companies
- Sector
- FHTX Health Care
- TEI Finance
- Exchange
- FHTX Nasdaq
- TEI Nasdaq
- Market Cap
- FHTX 237.4M
- TEI 256.5M
- IPO Year
- FHTX 2020
- TEI N/A
- Fundamental
- Price
- FHTX $5.23
- TEI $5.43
- Analyst Decision
- FHTX Strong Buy
- TEI
- Analyst Count
- FHTX 6
- TEI 0
- Target Price
- FHTX $13.17
- TEI N/A
- AVG Volume (30 Days)
- FHTX 163.3K
- TEI 142.4K
- Earning Date
- FHTX 03-06-2025
- TEI 01-01-0001
- Dividend Yield
- FHTX N/A
- TEI 10.51%
- EPS Growth
- FHTX N/A
- TEI N/A
- EPS
- FHTX N/A
- TEI N/A
- Revenue
- FHTX $25,515,000.00
- TEI N/A
- Revenue This Year
- FHTX N/A
- TEI N/A
- Revenue Next Year
- FHTX $8.30
- TEI N/A
- P/E Ratio
- FHTX N/A
- TEI N/A
- Revenue Growth
- FHTX N/A
- TEI N/A
- 52 Week Low
- FHTX $3.86
- TEI $4.35
- 52 Week High
- FHTX $10.25
- TEI $5.39
- Technical
- Relative Strength Index (RSI)
- FHTX 52.39
- TEI 57.48
- Support Level
- FHTX $3.89
- TEI $5.30
- Resistance Level
- FHTX $6.27
- TEI $5.42
- Average True Range (ATR)
- FHTX 0.59
- TEI 0.07
- MACD
- FHTX 0.11
- TEI -0.00
- Stochastic Oscillator
- FHTX 48.38
- TEI 56.52
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.